10X Genomics underperformed the S&P 500 market so far this year.
1 report, 1 independent
Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
10X Genomics underperformed the S&P 500 market so far this year.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- 10X Genomics stock fell short of S&P 500's gain on July 29, 2025.Sub-event
10X Genomics stock underperformed the S&P 500 market.1 source
Keep exploring
The entities involved
-
10X Genomics
American biotechnology company
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- Zacks10x Genomics (TXG) Surpasses Q2 Earnings and Revenue Estimates 10x Genomics (TXG) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per shar